Search

Displaying results 2961 - 2970 of 10000 in total
  1. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. … Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.

  2. Drug

    Phensuximide

    go.drugbank.com/drugs/DB00832
    Approved

    The frequency of attacks is reduced by depression of nerve transmission in the motor cortex. … Phensuximide is a member of the succinimide class with anticonvulsant properties.

  3. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    Microdystrophin is a truncated, functional form of dystrophin. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  4. Drug

    Quinupristin

    go.drugbank.com/drugs/DB01369
    Approved

    Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. … The combination of the two components acts synergistically and is more effective in vitro than each component alone.

  5. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    Methyprylon is a sedative of the piperidinedione derivative family that was previously used for the treatment of insomnia. … However, with the introduction of newer drugs with fewer side effects, such as benzodiazepines, the clinical use of methyprylon is now limited.

  6. Drug

    Perphenazine

    go.drugbank.com/drugs/DB00850
    ApprovedInvestigational

    An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.

    Products: TAKION 16 MG, PERPHENAZIN-NEURAX 8 MG
  7. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    This approval is based on positive results obtained from a multi-site, single-arm, externally controlled study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and … a 68% reduction in the risk of death were observed.

  8. Drug

    Molindone

    go.drugbank.com/drugs/DB01618
    Approved

    An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. … Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283)

  9. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Products: VOTRIENT® 200 MG, VOTRIENT® 400 MG
  10. Drug

    Cholecystokinin

    go.drugbank.com/drugs/DB08862
    ApprovedInvestigationalWithdrawn

    Cholecystokinin ( also known as _CCK or CCK-PZ_) is a peptide hormone of the gastrointestinal system which is responsible for stimulating the digestion of fat and protein. … This hormone has also been shown to have positive effects on enteric smooth muscle contraction and on nerve activity at multiple locations in the peripheral and central nervous system.